$AbbVie (ABBV.US)$ Aesthetics is a wrongfully underestimated...
$AbbVie(ABBV.US$ Aesthetics is a wrongfully underestimated asset in AbbVie. A reminder: Botox and other assets came with the recent acquisition of Allergan.
And these assets should be valued higher than other Pharma assets as there is no loss of exclusivity with Botox. This is a trademark and therefore the cash flow will be recurring for a long time.
And if you believe that Rinvoq and Skyrizi will be able to substitute, even partially, for Humira, then AbbVie appears very undervalued at a PE of 8.
A PE at 12 would be more appropriate. Which could get the stock to a level at 140 to 150.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
William Paul : DRIP 10 shares a month. My largest holding and best dividend growth stock!
fly up high William Paul: WHICH PAYS MONTHLY?
Indicator analyst William Paul: Do you mean to say buy 10s/m?
Drdrdoky : Yep, the fear mongering got it to $106 a couple months back and that’s where I grabbed 100 shares.
UANM5SC6Ea Drdrdoky: Had my parents jump in 106-108. I originally bought 111 and doubled down at 107
z45pL0OXH0 : AbbVie great company with lots of runway ahead! Great divvy! Longz ABBV! :-)